- Home
- |
- About
- |
- Products
- |
- News and Media
- |
- Investors
- |
- Online Pharmacy
- |
- Contact Us
Annual Declaration of Compliance for Purposes of California Health and Safety Code, §§ 119400-119402
April 5, 2023
Medicure has developed its Corporate Compliance Program in accordance with the "Compliance Program Guidance for Pharmaceutical Manufacturers," published by the Office of Inspector General, U.S. Department of Health and Human Services ("OIG Guidance") and the California Health and Safety Code, Part 15, Division 104, § 119400-119402. Medicure has adopted written policies and procedures to help ensure that we conduct our business affairs with honesty and integrity and in full compliance with all applicable laws, rules and regulations. Additionally, Medicure has adopted policies to ensure compliance with the Pharmaceutical Research and Manufacturers of America Code ("PhRMA Code"). A detailed description of Medicure's Corporate Compliance Program is published on our public website at, /corporate-compliance. Copies of the Medicure Corporate Compliance Program can also be obtained by calling 1-800-509-0544 then selecting option 3, then option 1 or by emailing compliance@medicure.com
The specific annual dollar limit that Medicure has placed on items or activities provided to a healthcare professional in California is $1,500.00. In addition, consistent with the California statute, the following items have been excluded from the annual limit:
Marketed Prescription Drug | Colorado WAC Disclosure Form |
---|---|
Aggrastat® (tirofiban hydrochloride) Injection | 2024-02-01 |
Zypitamag® (pitavastatin) tablets | 2024-02-01 |
House Bill 19-1131. Published by the General Assembly of the State of Colorado.
Please see full prescribing information for Aggrastat and Zypitamag
Leadership
Board of Directors
Our History
Mission and Values
Medicure Marks Its 25th Anniversary
People and Culture
Careers
AGGRASTAT® (tirofiban HCl) injection
Zypitamag®
Pipeline
Drug Safety
Medical Information
Patient Information
Events
Presentations / Conference Calls
Stock Information
Annual Reports
Quarterly Reports
Corporate Governance
Investor Contacts